Retention rate of acalabrutinib in a non-interventional setting - RETAIN

Study identifier:D8224R00001

ClinicalTrials.gov identifier:NCT05645172

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Retention rate of acalabrutinib in a non-interventional setting

Medical condition

Chronic lymphocytic leukaemia (CLL)

Phase

Phase 4

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

200

Study type

Observational

Age

18 Years - 99 Years

Date

Study Start Date: 12 Dec 2022
Estimated Primary Completion Date: 15 Apr 2026
Estimated Study Completion Date: 15 Apr 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria